2024
Mechanistic Differences between Torsemide and Furosemide.
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024 PMID: 39196651, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchTorsemide groupDiuretic doseTubular site of actionHigher diuretic dosesDose of furosemideProportion of dosesOral furosemideSite of actionPrescribed doseNeurohormonal activationMechanistic substudyClinical outcomesPharmacodynamic advantagesKidney dysfunctionPharmacodynamic parametersKidney functionRandomized trialsNatriuresisTubular sitesFurosemideTorsemideDoseTRANSFORM-HFPlasma volumeBody weight
2019
Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial
Patel RB, Alenezi F, Sun JL, Alhanti B, Vaduganathan M, Oh JK, Redfield MM, Butler J, Hernandez AF, Velazquez EJ, Shah SJ. Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. Journal Of Cardiac Failure 2019, 26: 270-275. PMID: 31857197, PMCID: PMC7078046, DOI: 10.1016/j.cardfail.2019.12.001.Peer-Reviewed Original ResearchConceptsLA reservoir strainLA myopathyHeart failureNT-proBNPEjection fractionLA reservoirReservoir strainLA strainN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideAtrial mechanical dysfunctionEjection Fraction trialLA contractile strainLower LA reservoirJugular venous pressurePoor clinical outcomePhosphodiesterase-5 inhibitionAssociation of LAAtrial myopathyBaseline echocardiogramRELAX trialNeurohormonal activationExercise capacityVenous pressureClinical outcomes
2003
Making Two Wrongs Right – Case of Using a Patient’s Diabetes insipidus to Treat HisHeart Failure: Experience with Vasopress in Antagonists from Animal Studies and Clinical Trials
Fischi M, Trichon B, Velazquez E, Blazing M, O’Conner C. Making Two Wrongs Right – Case of Using a Patient’s Diabetes insipidus to Treat HisHeart Failure: Experience with Vasopress in Antagonists from Animal Studies and Clinical Trials. Cardiology 2003, 3: 107-112. DOI: 10.1159/000071029.Peer-Reviewed Original ResearchHeart failureCongestive heart failure resultsSmooth muscle cell contractionHeart failure resultsCentral diabetes insipidusHeart failure casesMuscle cell contractionNonosmotic releaseNeurohormonal activationReceptor blockersNonischemic cardiomyopathyHypothalamic osmoreceptorsClinical trialsReceptor subtypesDiabetes insipidusAntidiuretic hormoneAnimal studiesMedical treatmentPosterior pituitaryExpression of aquaporinsPlasma osmolalityCell contractionPatientsBody waterCirculatory system